The FDA July 2026 Peptide Review

The FDA peptide review 2026 is the FDA’s July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting, where outside experts will discuss seven peptides: BPC-157, KPV, TB-500, and MOTS-c on day one, then Emideltide (DSIP), Semax, and Epitalon on day two. The FDA’s briefing position is that these seven should not be added to the 503A bulks list. As of publication, no peptide has been approved, legalized, or made available for sale. This is education, not medical advice; a licensed provider determines eligibility.

What the FDA peptide review 2026 is

These seven peptides had been sitting in Category 2 of the FDA’s Section 503A interim list, a designation for bulk drug substances the agency has flagged as potentially raising significant safety risks. Substances in Category 2 are effectively off-limits for pharmacy compounding while the FDA studies them. On April 15, 2026, the FDA announced the removal of 12 peptides from Category 2, a step that followed the withdrawal of those substances’ Category 2 nominations. That action set the stage for the review now scheduled for July.

Removing a substance from Category 2 is not the same as approving it. It means the peptides are no longer listed in Category 2 of the interim policy, because the nominations were withdrawn, which lets the PCAC review proceed. It does not clear them of safety questions. For seven of the 12 peptides, the next step is a scientific review by the Pharmacy Compounding Advisory Committee, a panel of outside experts that advises the FDA on which bulk substances belong on the 503A bulks list.

The seven peptides under review, and the schedule

The FDA referred seven of the 12 peptides to the Pharmacy Compounding Advisory Committee for scientific review at a two-day meeting on July 23 and 24, 2026. The agenda splits the work across the two days:

• July 23: BPC-157, KPV, TB-500, and MOTS-c.
• July 24: Emideltide (also called DSIP), Semax, and Epitalon.

Five additional peptides are slated for a separate PCAC meeting scheduled before the end of February 2027. The committee’s job is to weigh the available scientific evidence and vote a recommendation. That recommendation is exactly that: a recommendation. The FDA is not bound by it, and the agency makes the final call through its own rulemaking process.

What “Category 2 removal” does and does not mean

This is the part that is easiest to get wrong, and the part that matters most. Removal from Category 2 does not authorize compounding. It does not place any of these peptides on the 503A bulks list. It does not make them “FDA-approved,” and it does not make them legal to buy for personal use.

Here is the distinction that clears up most of the confusion. Being on the 503A bulks list only means the FDA has determined, through formal rulemaking, that a bulk substance may be used in patient-specific compounding by a licensed pharmacist working from a valid prescription. It is a permission to compound, not an endorsement of a finished product, and not a marketing approval. None of the seven peptides under review is currently on that list, and none is an approved drug.

Where these peptides stand today

As of publication, the outcome is a proposal and an advisory-committee review, not a final rule. The seven peptides are not approved, not legalized, and not available through any lawful channel for human use. The “research chemical” vendors that sell BPC-157, TB-500, and similar compounds online are not a lawful route for human use. Those products are typically labeled “not for human consumption” and are not manufactured, tested, or labeled to pharmaceutical standards.

The FDA’s position going into the meeting

It is worth being precise about who wants what. The FDA’s briefing materials for the July meeting state that these seven peptides should not be added to the 503A bulks list. In other words, the agency’s own scientists are asking their advisory committee to agree that the evidence does not yet support routine compounding of these substances.

The policy backdrop has been widely covered. HHS Secretary Robert F. Kennedy Jr. has publicly championed broader peptide access, including in remarks on February 27, 2026, and described the Category 2 removal, as reported by BioPharma Dive in April 2026, as “a long-overdue action to restore science, accountability and the rule of law.” It is important to attribute this carefully: the reclassification was an FDA action, not a personal directive, and the Secretary was not the formal announcer. The scientific question still runs through PCAC and the FDA’s rulemaking process.

Safety, evidence, and why the source matters

The committee exists to answer a narrow scientific question: is there enough evidence that a given bulk substance can be compounded safely and effectively for it to belong on the 503A list? For the seven peptides in question, the FDA’s stated view going into the meeting is that the answer, for now, is no.

From a patient-safety standpoint, the sourcing issue is the immediate concern. A peptide bought from an unregulated vendor has no guarantee of identity, purity, sterility, or dose. Contamination, incorrect concentration, and mislabeling are real risks when a product sits outside the pharmacy supply chain. This is a large part of why the distinction between a licensed prescription pathway and a “research chemical” purchase is not a technicality. It is the difference between a product a clinician can stand behind and one no one is accountable for.

Who this is relevant to

If you have been reading about BPC-157 or TB-500 and wondering whether the July meeting means you can now obtain them, the honest answer is no, not through any approved or listed route. If you are exploring legitimate, prescription peptide or hormone therapy for a specific clinical reason, that pathway is unchanged: it requires an evaluation by a licensed provider, a valid prescription, and dispensing through a licensed pharmacy.

Regulatory status at a glance

The table below compares where the peptides under review stand against the prescription therapies a licensed provider may actually offer. It is a snapshot as of publication in July 2026.

Substance or category	FDA-approved drug?	On the 503A bulks list (may be compounded)?	Under PCAC review in 2026?	Lawful route for human use today
BPC-157, KPV, TB-500, MOTS-c	No	No	Yes, July 23, 2026	None as an approved or listed compounding substance
Emideltide (DSIP), Semax, Epitalon	No	No	Yes, July 24, 2026	None as an approved or listed compounding substance
Sermorelin, enclomiphene (prescription compounded therapy)	No, not FDA-approved	Compounded under 503A with a valid prescription	Not part of this review	Prescription from a licensed provider, dispensed by a licensed pharmacy
GLP-1 medications (branded and compounded)	Branded products yes; compounded versions no	Varies by product	Not part of this review	Prescription from a licensed provider, dispensed by a licensed pharmacy

How Revive approaches this

Revive is a LegitScript-certified telehealth clinic, and our position on the July review is straightforward. We do not sell BPC-157, TB-500, or other research-chemical peptides, and nothing about the PCAC meeting changes that. We treat this event as what it is: a clarification of the legal landscape, not a green light.

What we do offer is a provider-led pathway for therapies that are appropriate to prescribe. Every plan starts with a licensed provider who reviews your history, confirms whether a given therapy is a fit, and determines eligibility before anything is dispensed. If a therapy is not appropriate for you, the answer is no. You can read more about that process on our how it works page. The short version: prescription therapy runs through a licensed provider and a licensed pharmacy, and we think that is the only responsible way to do it.

As the FDA’s rulemaking and the next PCAC meeting (set before the end of February 2027) play out, the framework will keep evolving. We will keep our guidance tied to what the agency actually decides, not to what the internet hopes it will.

Frequently asked questions

What is the FDA peptide review 2026?

It is the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026, where outside experts review seven peptides that were removed from Category 2 of the Section 503A list in April 2026. The committee will recommend whether these peptides should be added to the 503A bulks list. The recommendation is advisory; the FDA makes the final decision through rulemaking.

Does the review mean BPC-157 is now FDA-approved or legal to buy?

No. Removal from Category 2 does not approve, legalize, or authorize the sale of BPC-157 or any of the other peptides under review. None of them is an approved drug, and none is on the 503A bulks list. As of publication, there is no lawful route to obtain them for human use through an approved or listed channel.

Which peptides are being reviewed, and when?

Seven peptides are on the July 2026 agenda. On July 23, the committee reviews BPC-157, KPV, TB-500, and MOTS-c. On July 24, it reviews Emideltide (also called DSIP), Semax, and Epitalon. Five additional peptides are scheduled for a separate PCAC meeting before the end of February 2027.

What does removal from Category 2 actually change?

By itself, very little for patients right away. The peptides are no longer listed in Category 2 of the interim policy because the nominations were withdrawn, which allows the PCAC review to proceed. It does not clear them of safety questions, authorize compounding, add anything to the 503A bulks list, or create a legal way to buy these peptides.

Is it safe to buy peptides from a research chemical website?

Buying peptides such as BPC-157 or TB-500 from “research chemical” vendors is not a lawful route for human use. These products are typically labeled “not for human consumption” and are not manufactured, tested, or labeled to pharmaceutical standards, so their identity, purity, sterility, and dose are not guaranteed. Talk to a licensed provider before considering any peptide.

Does Revive sell BPC-157 or TB-500?

No. Revive does not sell BPC-157, TB-500, or other research-chemical peptides. Revive offers provider-led, prescription-based therapies where appropriate, such as sermorelin, enclomiphene, and GLP-1 medications, each determined by a licensed provider after an evaluation.